Virios Therapeutics, Inc.

Good morning and welcome to Vireos Therapeutics First Quarter 2021 Financial Results Conference Call. Please be advised that today's call is being recorded at the company's request. At this time, I'd like to turn the call over to Angela Walsh, SVP Finance and Treasurer of Vireos Therapeutics.

Please proceed, Angela.

Thank you. Good morning, everyone, and thank you for joining us on today's conference call. We are pleased to be with you today to discuss various therapeutic first quarter financial results, as well as to provide you with an update on the operational progress we have made during the first four months of 2021. Please note that our financial results press release is now available on our website. We'll start today's call with our CEO, Greg Duncan, providing you with a brief update on our corporate progress during the past quarter. Dr. Mike Genro, our Chief Medical Officer, will bring further specifics on our fibromyalgia Phase IIb study and our chronic toxicology programs. And then I will return to review our Q1 financial results. In addition, Ralph Groswald, our VP of Operations, is with us for the question and answer portion of the call. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties that can cause actual results to differ materially. Any forward-looking statements are made only as of today, and we disclaim any obligation to update these forward-looking statements other than as required by law. Please see the forward-looking statements disclaimer in our financial results release issued this morning and the risk factors in the company's current and subsequent filings with the SEC. It is now my pleasure to turn the call over to our CEO, Greg Duncan. Greg?